CancerBot

What CancerBot does

CancerBot is an AI-powered clinical trial matching platform that helps cancer patients find trials they are truly eligible for, without requiring medical expertise. Patients sign up for free through a web and app interface, answer guided questions about their diagnosis, lab values, biomarkers, and treatment history, and receive a personalized, ranked list of trials in minutes. The core matching engine, called EXACT (Eligibility eXpression Against Clinical Trials), extracts structured eligibility attributes from unstructured clinical trial text using NLP and evaluates each criterion individually against the patient's structured record, producing explicit pass/fail/indeterminate verdicts rather than relying on keyword search. Patient data is stored in CTOMOP, a data model built on the OMOP Common Data Model, and the platform supports FHIR-based ingestion of external health records. Trials are then ordered using a Goodness Scoring rubric that weights each match by patient-stated preferences for risk, benefit, burden, and distance. CancerBot monetizes by offering its EXACT matching technology free to disease foundations and patient support organizations as a white-label/embedded service, and indirectly through partnerships with pharmaceutical companies and research institutions seeking precisely screened patient populations; the patient-facing service is free and the Terms of Service restricts use to personal, non-commercial purposes. The company was founded by Adam Blum, a serial AI entrepreneur and follicular lymphoma survivor, and was acquired by HealthKey.AI in June 2026, which builds open infrastructure for disease-specific patient communities and provides PHRAME personal health record components. Following the acquisition, CancerBot's matching engine is being embedded across HealthKey-powered disease communities serving multiple myeloma, follicular lymphoma, CLL, and mantle cell lymphoma patients, with deeper FHIR/OMOP integration for richer patient records at the point of matching.

Name

CancerBot

Legal name

CancerBot, Inc.

Website

https://cancerbot.org

Company type

Private

Founded year

2020

Operating status

Acquired

Headcount range

1–10 employees

Short description

CancerBot is an AI-powered clinical trial matching platform that uses structured eligibility evaluation to match cancer patients with trials they truly qualify for, offering free patient access and white-label matching to disease foundations via its HealthKey.AI parent platform.

Ownership category

akta.pro rank

Product category

Clinical Trial Matching Software

NAICS

Medical and Diagnostic Laboratories (62151)

SIC

Services-Health Services (8000), Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials) (HLAAANAI)

akta.pro secondary industries

Oncology Pathways & Precision Medicine Decision Support (HLACAGAH), Clinical & Claims Data Integration for Population Health (payer-provider data fusion) (HLACAHAI)

Keywords

• Clinical trial matching
• Cancer patient eligibility
• AI precision matching
• Patient recruitment oncology
• Structured eligibility extraction

Headquarters

HQ city

Fair Oaks

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Free Patient Service: CancerBot provides its clinical trial matching service free of charge to patients. The business model relies on partnerships with pharmaceutical companies, research institutions, and disease foundations rather than direct patient fees.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

CancerBot provides an AI-powered patient-facing clinical trial matching platform for cancer patients. Using its proprietary EXACT system, it extracts structured eligibility criteria from unstructured trial text and evaluates patient records criterion-by-criterion with pass/fail/indeterminate verdicts. Matched trials are ranked using Goodness Scoring based on patient preferences for risk, benefit, burden, and distance. The service is free to patients and available via web app at app.cancerbot.org, with the EXACT engine also offered free to disease foundations and patient support organizations.

Product overview

CancerBot is an AI-powered clinical trial matching platform built on precision matching technology. The core product consists of the CancerBot user-facing application (currently at V2) and the underlying EXACT open-source matching system. EXACT performs structured eligibility evaluation by extracting attributes from unstructured trial text and matching criterion-by-criterion against structured patient records in the CTOMOP data model (built on OMOP CDM). The platform ranks matched trials using Goodness Scoring based on patient preferences for risk, benefit, burden, and distance. Following HealthKey.AI's acquisition, CancerBot is integrated into the HealthKey ecosystem with access to PHRAME PHR infrastructure for richer patient records.

Differentiator

Problem solved

Functional benefit

Products and services

• CancerBot AI-powered patient-facing clinical trial matching platform that uses structured eligibility evaluation to match cancer patients with clinical trials they truly qualify for. Patients answer guided questions about their diagnosis, lab values, and treatment history to receive personalized trial recommendations ranked by goodness score. Free for patients via web app at app.cancerbot.org.
• EXACT Clinical Trial Matching System EXACT (Eligibility eXpression Against Clinical Trials) is an open-source precision clinical trial matching system that creates structured databases from unstructured trial text and performs criterion-by-criterion eligibility matching. Offered free to disease foundations and patient support organizations to integrate into their community platforms. The foundational technology underlying CancerBot.

Quantifiable outcome

• Patients who qualify for trials they would otherwise never hear about
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability6 records

Feature5 records

Partnerships

One partnership is on record.

• HealthKey.AIcoreStrategic or Co-development Partner · 24 June 2026HealthKey.AI acquired CancerBot in June 2026. HealthKey builds open infrastructure for disease-specific patient communities. CancerBot's EXACT trial matching becomes part of HealthKey's platform serving foundations and patients across multiple disease types. The acquisition enables CancerBot to leverage HealthKey's PHRAME infrastructure for richer patient records and standard data formats while CancerBot focuses on improving the matching engine.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• xCures: xCures uses AI to structure patient records and identify clinical trial and treatment options for cancer patients. Overlaps with CancerBot's structured patient data model and cancer-focused matching, though xCures has a different emphasis on real-world evidence generation.
• Power Life Sciences: Power (formerly Trials.ai) applies AI to clinical trial patient matching and site selection, serving pharma and CROs. Comparable AI-driven matching focus but different primary buyer (enterprise/sponsor vs CancerBot's DTC patient funnel).
• Carebox: Carebox offers AI-powered clinical trial matching and patient navigation for cancer patients, working with hospitals, pharma, and foundations. Similar patient-facing matching focus and oncology emphasis, with comparable foundation-led distribution angles.

Direct peers

• Mendel.ai: Mendel.ai applies AI to clinical trial feasibility and patient matching, organizing unstructured medical record data for trial recruitment. Comparable technology stack (LLM/NLP on unstructured clinical text) and overlapping customer base of pharma and CROs.
• Clara Health: Clara Health is a patient-centric clinical trial matching and concierge service, with strong DTC positioning similar to CancerBot. Competes for the same oncology patient funnel and pharma-sponsored recruitment budgets.
• Deep 6 AI: Deep 6 AI uses AI and NLP to match patients to clinical trials by mining EHR data. Directly comparable to CancerBot's EXACT technology in applying structured eligibility extraction against patient records, though Deep 6's go-to-market is enterprise/site-level rather than DTC consumer.
• EmergingMed: EmergingMed provides oncology-focused clinical trial matching and navigation services to patients and advocacy organizations. Comparable in disease-specific patient community GTM (especially through cancer foundations) and trial-matching services.
• Antidote: Antidote (now part of Eversana) is a digital patient recruitment and clinical trial matching platform that connects patients to trials across multiple therapeutic areas. Direct competitor to CancerBot, with similar DTC patient-facing matching and pharma B2B monetization, though CancerBot's EXACT system emphasizes criterion-by-criterion structured eligibility extraction.
• Massive Bio: Massive Bio provides AI-powered cancer clinical trial matching and enrollment services to patients and pharma sponsors. Comparable to CancerBot in oncology focus, DTC patient funnel, and pharma-driven revenue model, with similar pain point of accelerating trial recruitment.

Broad incumbents

• ClinicalTrials.gov: The NIH-operated registry is the authoritative source for clinical trial listings and the underlying data CancerBot extracts from. It is the broad incumbent in trial discovery, though it lacks CancerBot's AI-powered patient-matching, criterion-by-criterion evaluation, and personalized goodness scoring.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cancerbot

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CancerBot